Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Steven G. Nadler"'
Autor:
Laurence C. Menard, Paul Fischer, Bijal Kakrecha, Peter S. Linsley, Erik Wambre, Maochang C. Liu, Blake J. Rust, Deborah Lee, Becky Penhallow, Nataly Manjarrez Orduno, Steven G. Nadler
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Checkpoint inhibitors target the inhibitory receptors expressed by tumor-infiltrating T cells in order to reinvigorate an anti-tumor immune response. Therefore, understanding T cell composition and phenotype in human tumors is crucial. We analyzed by
Externí odkaz:
https://doaj.org/article/e80faafa91584f1aba7c64031aee6461
Autor:
Nataly Manjarrez-Orduño, Laurence C. Menard, Selena Kansal, Paul Fischer, Bijal Kakrecha, Can Jiang, Mark Cunningham, Danielle Greenawalt, Vishal Patel, Minghui Yang, Ryan Golhar, Julie A. Carman, Sergey Lezhnin, Hongyue Dai, Paul S. Kayne, Suzanne J. Suchard, Steven H. Bernstein, Steven G. Nadler
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Agents targeting the PD1–PDL1 axis have transformed cancer therapy. Factors that influence clinical response to PD1–PDL1 inhibitors include tumor mutational burden, immune infiltration of the tumor, and local PDL1 expression. To identify peripher
Externí odkaz:
https://doaj.org/article/9c0d0121b6ce4399a93cc25cb09ce921
Autor:
Suzanne J. Suchard, Somnath Bandyopadhyay, Sium Habte, Sherif Daouti, Steven G. Nadler, Selena Kansal, Richard Furie, Deborah Lee, Julie Carman, Nataly Manjarrez-Orduño, Francesca Casano, Laurence Menard, Can Jiang, Yanhua Hu
Publikováno v:
ImmunoHorizons. 1:124-132
Systemic lupus erythematosus (SLE) is a highly heterogeneous disease with limited therapeutic options, where clinical manifestations are the result of activation of innate and adaptive immune mechanisms. The elucidation of these mechanisms is critica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e8542d3df7ed5f671c98110437c80ea
https://doi.org/10.4049/immunohorizons.1700028
https://doi.org/10.4049/immunohorizons.1700028
Autor:
Hui Zhang, Gerald J. Berry, Steven G. Nadler, Ryu Watanabe, Cornelia M. Weyand, Jörg J. Goronzy
Publikováno v:
Oral Presentations.
Background Giant cell arteritis (GCA) is a granulomatous vasculitis of medium and large arteries. In GCA-affected arteries, vascular wall is destroyed by tissue-infiltrating CD4 T cells and macrophages, which leads to intramural neoangiogenesis, inti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::871b1674a090c8fed6df0531633e9cb2
https://doi.org/10.1136/annrheumdis-2019-eular.1233
https://doi.org/10.1136/annrheumdis-2019-eular.1233
Autor:
Hui Zhang, Gerald J. Berry, Cornelia M. Weyand, Ryu Watanabe, Jörg J. Goronzy, Steven G. Nadler
Background In giant cell arteritis, vessel-wall infiltrating CD4 T cells and macrophages form tissue-destructive granulomatous infiltrates, and the artery responds with a maladaptive response to injury, leading to intramural neoangiogenesis, intimal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::911aa817e1cd808f600ffee6f42a58b4
https://europepmc.org/articles/PMC6709860/
https://europepmc.org/articles/PMC6709860/
Autor:
Sidney Pitt, John S. Sack, Vicky Tang, William J. Pitts, Steven H. Spergel, Jonathan Lippy, Junqing Guo, Michael Galella, Mertzman Michael E, Sylwia Stachura, Steven G. Nadler, Aberra Fura, Percy H. Carter, Gary L. Schieven, Luisa Salter-Cid, Kim W. McIntyre, James Kempson, Javed Khan, Lauren Haque, Rosemary Zhang, John S. Tokarski, Guoxiang Shen, Kathleen M. Gillooly, Stephen T. Wrobleski, Joel C. Barrish
[Image: see text] The four members of the Janus family of nonreceptor tyrosine kinases play a significant role in immune function. The JAK family kinase inhibitor, tofacitinib 1, has been approved in the United States for use in rheumatoid arthritis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1a959ab8edd802fd477e946d59e0fb
https://europepmc.org/articles/PMC6421541/
https://europepmc.org/articles/PMC6421541/
Autor:
Rui-Ru Ji, Paul Garside, Steven G. Nadler, James M. Brewer, William Weir, Agapitos Patakas, Sean E. Connolly, Iain B. McInnes, Robert A. Benson
Publikováno v:
Arthritis & Rheumatology. 68:627-638
Objective To determine at the phenotypic, functional, and transcriptional levels whether abatacept, a CTLA-4Ig molecule that binds with high affinity to CD80/86 on antigen-presenting cells (APCs) and is used to treat rheumatoid arthritis, induces a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d04582338633a1ff2c01584102e272db
https://doi.org/10.1002/art.39470
https://doi.org/10.1002/art.39470
Autor:
Karyn O'neil, Robert V. Kolakowski, Steven G. Nadler, Kulkarni Swapnil, Addis Russell C, Joshua Gorsky, Xin Yao, Evana Mortezavi, Rebecca Meyer
Publikováno v:
Cancer Research. 80:1825-1825
KRAS has been the quintessential undruggable oncogene for many years. Although there have been recently described small molecule inhibitors of KRAS, these molecules only target a specific mutant form, KRAS G12C. The KRAS G12C mutation represents just
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5dd17c204bd86403ef2b998a8e50748
https://doi.org/10.1158/1538-7445.am2020-1825
https://doi.org/10.1158/1538-7445.am2020-1825
Autor:
Paul Fischer, Peter S. Linsley, Bijal Kakrecha, Laurence Menard, Nataly Manjarrez Orduno, Erik Wambre, Steven G. Nadler, Blake J. Rust, Becky Penhallow, Deborah Lee, Maochang Liu
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 9 (2018)
Frontiers in Immunology, Vol 9 (2018)
Checkpoint inhibitors target the inhibitory receptors expressed by tumor-infiltrating T cells in order to reinvigorate an anti-tumor immune response. Therefore, understanding T cell composition and phenotype in human tumors is crucial. We analyzed by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::754096b4626bb0ec94e2cab0fc206567
http://europepmc.org/articles/PMC6275222
http://europepmc.org/articles/PMC6275222
Autor:
Paul S. Kayne, Selena Kansal, Mark D. Cunningham, Can Jiang, Julie Carman, Minghui Yang, Danielle Greenawalt, Suzanne J. Suchard, Laurence Menard, Sergey Lezhnin, Steven H. Bernstein, Paul Fischer, Bijal Kakrecha, Nataly Manjarrez-Orduño, Steven G. Nadler, Vishal Patel, Hongyue Dai, Ryan Golhar
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 9 (2018)
Frontiers in Immunology, Vol 9 (2018)
Agents targeting the PD1-PDL1 axis have transformed cancer therapy. Factors that influence clinical response to PD1-PDL1 inhibitors include tumor mutational burden, immune infiltration of the tumor and local PDL1 expression. To identify peripheral co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d1ef1f308377ee6fb0c6e0bf2e306ed
https://pubmed.ncbi.nlm.nih.gov/30123214
https://pubmed.ncbi.nlm.nih.gov/30123214